Correlation between clinical activity and serological markers in a wide cohort of patients with systemic lupus erythematosus: An eight-year prospective study

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 60-66

  Villegas Zambrano, Neifred ^a   Martínez Taboada, Victor M ^a   Bolívar, Ainhoa ^a   Martín, María San ^a   Alvarez, Lorena ^a   Marín, María José ^a   López Hoyos, Marcos ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anti dsDNA antibodies; Immunofluorescence; Nephritis; SLEDAI

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4 BINDING PROTEIN; DOUBLE STRANDED DNA ANTIBODY;

ADULT; ANTIBODY TITER; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; CONFERENCE PAPER; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PATIENT MONITORING; PROSPECTIVE STUDY; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 69949126451     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04650.x     Document Type: Conference Paper

References (25)

1. Hahn, B.H. 1998. Antibodies to DNA. N. Engl. J. Med. 338: 1359-1368.
2. Munoz, L.E. et al. 2008. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Au-toimm. Rev. 7: 594-597.
3. Lloyd, W. & P.H. Schur. 1981. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine 60: 201-217.
4. Yang, Y. et al. 2004. The intricate role of complement C4 in human SLE. In Complement in Autoimmunity Vol. 7: Current Directions in Autoimmunity. G.C. Tsokos, Ed. Karger. Basel.
5. Isenberg, D. & R. Smeenk. 2002. Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now? Lupus 11: 797-800.
6. Spronk P.E., P.C. Limburg & C.G. Kallenberg. 1995. Serological markers of disease activity in systemic lupus erythematosus. Lupus 4: 86-94.
7. Neogi, T. et al. 2006. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J. Rheumatol. 33: 1785-1788.
8. Brinkman, K. et al. 1991. The specificity of the anti-dsDNA ELISA. A closer look. J. Immunol. Methods 139: 91-100.
9. Hernando, M. et al. 2002. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoas-say. Clin. Chem. Lab. Med. 40: 1056-60.
10. Bardin, N., C. Ragot & M. Sanmarco. 2007. Clinical evaluation of a new quantitative enzyme-linked im-munosorbent assay for detection of double-stranded DNA autoantibodies. Ann. N. Y. Acad. Sci. 1109: 511-518.
11. Ghirardello, A. et al. 2007. Evaluation of the current methods for the measurement of serum anti-double stranded DNA antibodies. Ann. N. Y. Acad. Sci. 1109: 401-406.
12. Lopez-Hoyos, M. et al. 2004. Clinical utility of antibodies to double-stranded DNA by a new im-munofluorescence test. Lupus 13: 144-147.
13. Lopez-Hoyos, M. et al. 2005. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus. Lupus 14: 505-509.
14. TerBorg, E.J. et al. 1990. Measurement of increasees of anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus ery-thematosus: a long-term, prospective study. Arthritis Rheum. 33: 634-643.
15. Tan E.M. et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277.
16. Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40: 1725.
17. Bombardier, C. et al. 1992. The Committee on prognosis studies in SLE. Arthritis Rheum. 35: 630-640.
18. Gladman D.D., D. Ibanez & M.B. Urowitz. 2002. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29: 288-291.
19. Ho, A. et al. 2001. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 44: 2342-2349.
20. Bootsma, H. et al. 1995. Prevention of relapses in systemic lupus erythematosus. Lancet 345: 1595-1599.
21. Esdaile, J.M. et al. 1996. Laboratory tests as predictors of disease exacerbations in systemic lupus ery-thematosus: why some tests fails. Arthritis Rheum. 39: 370-378.
22. LeBlanc, B.A., D.D. Gladman & M.B. Urowitz. 1994. Serologically active clinically quiescent systemic lupus erythematosus: Predictors of clinical flares. J. Rheumatol. 21: 2239-2241
23. Swaak, A.J.G. et al. 1979. AntidsDNA and complement profiles as prognostic guide in systemic lupus erythematosus. Arthritis Rheum. 22: 226-235
24. Düzgün, N. et al. 2007. Antinucleosome antibodies and systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1109: 421-428. (Pubitemid 47511385)
25. Andreoli, L. et al. 2008. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? J. Autoimmun. 30: 51-57.